Empagliflozin in type 2 diabetes: Added benefit not proven

The results of a study on the effectiveness of Empagliflozin in the treatment of type 2 diabetes could not be proven. One research question could not be evaluated. The indirect comparisons were also not evaluable. For other research questions, data were lacking. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *